Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The data, spotted by an analyst at Cantor Fitzgerald, focused on concerns about potential side effects with the drug, called MariTide. Once they were shared widely in an investor note, the company’s ...

Amgen Inc. (NASDAQ: AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...